Trastuzumab envedotin clinical trials
Also written DP303c.
How each study uses trastuzumab envedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the trastuzumab envedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (6) · Shanghai Runshi Pharmaceutical Technology Co., Ltd (1)
Studies
Open first, then newest update. How each study uses trastuzumab envedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 1/2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06577376Written as DP303c
- DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast CancerRecruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06313086Written as DP303c
- DP303c in Patients With HER2-positive Advanced Breast CancerNot yet recruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05901935Written as DP303c
- A Study of DP303c in Patients With HER2-positive Advanced Solid TumorsStatus unknownPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05810103Written as DP303c
- DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast CancerStatus unknownPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05334810Written as DP303c
- Study of DP303c Injection in Patients With Advanced Ovarian CancerStatus unknownPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04828616Written as DP303c injection
- Study of DP303c Injection in Patients With Advanced or Metastatic Gastric CancerStatus unknownPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04826107Written as DP303c treatment
Given beside what is tested · 1 — trastuzumab envedotin is usual care or a partner of the new treatment
Codes
What other systems call trastuzumab envedotin · ClinicalTrials.gg INT014610
- UNII (FDA) 37DMF82G1FTRASTUZUMAB ENVEDOTINOne source FDA
- NCI Thesaurus C173962Trastuzumab EnvedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 37DMF82G1F | TRASTUZUMAB ENVEDOTIN | One source FDA |
| NCI Thesaurus | C173962 | Trastuzumab Envedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.